

Special Issue

Recent Advances in Non-muscle Invasive Bladder Cancer

Message from the Guest Editor

Non-muscle invasive bladder cancer represents a wide disease spectrum. Risk stratification based on tumor size, number, grade, and T stage guides treatment and surveillance protocols. Continued advancements have led to a rapid evolution in the management of non-muscle invasive disease. Endoscopic techniques have expanded past traditional monopolar resection to include en-bloc laser-based resections. More options are now available to enhance disease surveillance following resection, including enhanced cystoscopy and new urine-based markers to evaluate for disease recurrence. Multiple efforts have been completed and are underway to expand options for adjuvant therapy following tumor resection. This includes BCG naive intermediate and high-risk non-muscle invasive disease and BCG refractory disease. Trials evaluating intravesical therapy include viral-based treatment, chemotherapy, and the combination of systemic immunotherapy and targeted therapy. This Special Issue will highlight the current state of the art in the diagnosis, management and surveillance of non-muscle invasive bladder cancer.

Guest Editor

Prof. Dr. Paul L. Crispen

Department of Urology, University of Florida, Gainesville, FL 32611, USA

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/179784

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)